

Index

A

- Ablative technologies, 90
- Activities of daily living (ADL), 23, 24
- Adjuvant therapy
 - CGA, 112–114
 - chemotherapy regimens, 119–120
 - disease-free survival and overall survival, 118
 - evaluation process and management, 120
 - guidelines, 123
 - inclusion and exclusion criteria, 116–117
 - life expectancy, 115
 - MOSAIC trial, 118–119
 - practical management
 - chemotherapy potential evaluation, 122
 - general condition evaluation, 121
 - safety profile evaluation, 122–123

Ageing

- AMP kinase, 12
- causes, 11
- insulin/IGF-1, 12
- interventions, 13–14
- senescence and mortality, 14–15
- sitruins, 13
- telomeres, 13
- TOR, 12
- American Joint Committee in Cancer (AJCC), 112
- American Society of Anesthesiologists physical status class (ASA class), 22–23
- AMP kinase, 12
- Argon plasma coagulation, 73

B

- Bevacizumab
 - efficacy outcomes, 147–148
 - observational, expanded use studies, 144–145

- polychemotherapy plus bevacizumab, 147
- RCT, 142–144
- related adverse events, 147, 149
- single-agent CT plus bevacizumab, 145–147

- Brachytherapy, 102–103
- British FOCUS 2 trial, 133–134
- British Geriatric Society, 33

C

- Cardiopulmonary exercise testing (CPET), 86
- Cetuximab
 - age nonselected studies, 150–152
 - prospective studies, 153–154
 - retrospective studies, 152–153
- CGA. *See* Comprehensive geriatric assessment (CGA)
- Charlson comorbidity index (CCI), 22, 103
- Chemoradiotherapy (CRT), 98
- Chemotherapy, 101–102
 - clinical trials
 - British FOCUS 2 trial, 133–134
 - FOCUS 2 *vs.* FFCD, 134
 - French FFCD group, 134
 - phase II studies, 135–137
 - risk score, 135, 138
 - meta-analyses
 - age groups, 132
 - 5-FU/FA monotherapy, 132–133
 - pooled analyses, 130–131
 - metastatic colorectal cancer, 129–130
- Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH), 135
- Chromosomal instability (CIN), 9, 10
- Colon cancer, 56–58
- Colonic stenting, 69–71

- Colorectal liver metastases (CRLMs), 82
- Comorbidity
 - ASA class and CACI scores, 22–23
 - definition, 21
 - effects, 22
 - PACE study, 23
- Comprehensive Cancer Center South study, 54–55
- Comprehensive Cancer Centre West (CCCW), 57–58
- Comprehensive geriatric assessment (CGA), 68–69
 - abbreviated CGA, 44–45
 - adjuvant therapy, 112–114
 - administration, 46
 - cancer management and, 48
 - comorbidity assessment, 41–42
 - components, 41
 - CRC and, 49
 - definition, 40
 - effects, 42–43
 - evaluation, 44
 - geriatricians and, 47–48
 - needs, 40–41
 - palliative surgery, 68–69
 - patient selection, 43–44
 - undertaking of, 46–47
 - uses, 45
- Computerized tomographic colonography (CTC), 34
- Cryoablation, 90
- CRYSTAL and OPUS trials, 151–152
- D**
- Dementia, 26
- Diagnosis, 33–34
- Disability, 23–24
- E**
- Eindhoven Cancer Registry, 2
- Enhanced recovery after surgery (ERAS) program, 35
- Epidemiology
 - anatomical subsite, 5
 - comorbidity, 3–5
 - diagnostic stage, 6
 - gender, 3
 - incidence, 2–3
 - prevalence, 7
 - socioeconomic status, 6
 - survival, 6–7
- Epidermal growth factor receptor (EGFR) cetuximab
 - age nonselected studies, 150–152
 - prospective studies, 153–154
 - retrospective studies, 152–153
- KRAS mutations, 150
- panitumumab, 154–155
- safety and efficacy data, 155–156
- F**
- Fearon-Vogelstein model, 9–10
- Fecal occult blood test (FOBT), 30
- FOLFOX and XELOX, 118, 122
- Frailty, 25
- G**
- Genetic alteration
 - carcinogenesis process, 10
 - chromosomal instability, 9–10
 - CRC prevention and therapy, 10–11
 - DNA methylation, 10
 - human ageing
 - AMP kinase, 12
 - causes, 11
 - insulin/IGF-1, 12
 - interventions, 13–14
 - senescence and mortality, 14–15
 - sitruins, 13
 - telomeres, 13
 - TOR, 12
 - microsatellite instability, 10
 - mutational profile, 15–17
- Geriatric assessment (GA), 38 *See also* Comprehensive geriatric assessment (CGA)
- Geriatric syndromes
 - delirium, 24
 - dementia, 26
 - features, 24
 - frailty, 25
 - surgery and hospitalization, 24–25
- H**
- Health-related quality of life (HRQOL), 101
- Hepatic resection, 72, 73
- High-dose rate intraluminal brachytherapy (HDR-ILBT), 102
- I**
- Insulin-like growth factor (IGF-1), 12

K

Kinase target of rapamycin (TOR), 12

L

Liver metastases

- ablative technologies, 90
- epidemiology and surgical considerations, 82–83
- liver resection, 87–90
- neoadjuvant chemotherapy and liver surgery, 84–86
- physiological changes, 83–84
- preoperative assessment, 86–87
- SIRT, 92
- TACE, 92

Liver resection, 87–90

M

Metastatic colorectal cancer (mCRC). *See* Chemotherapy; Targeted therapy, mCRC

Microsatellite instability (MSI), 10

Microwave ablation, 90

MOSAIC trial, 118–119

N

Nd:YAG laser ablation, 73

Neoadjuvant chemotherapy and liver surgery, 84–86

O

Overall survival (OS), 86

P

Palliative care

- adverse effects, 168
- antitumor treatment, 166
- chances and risks, 166–167
- clinical benefit, 167
- conditions of hope, 164
- contents, 165–166
- curative vs. palliative care, 163–164
- cured fraction and uncured patient survival, 162–163
- mutual understanding importance, 169
- patient rights, 169
- quality of life, 169–170

Palliative surgery

- CGA, 68–69

colonic stenting, 69–71

emergency colorectal

presentation, 67–68

stage IV colorectal cancer management

advanced inoperable disease and

asymptomatic, 74

hepatectomy, 72–73

issues, 66–67

laparoscopic approach, 71–72

Nd:YAG laser ablation and argon

plasma coagulation, 73–74

Panitumumab, 154–155

Patient assessment

GA, 36

surgical outcomes, 34–35

Performance status (PS), 86

Preoperative assessment of cancer patients (PACE), 23

Q

Quality of life, 169–170

R

Radiofrequency ablation (RFA), 90

Radiotherapy, rectal cancer

acute toxicity, 99–100

assessment, 103–104

brachytherapy, 102–103

chemotherapy, 101–102

comorbidity, 97

fractionation/radiation schedules, 102

functional outcomes, 100–101

HRQOL, 101

incidence, 95–96

late toxicity, 100

local recurrence rates, 96

randomized clinical trials, 98–99

retrospective nonrandomized studies, 99

second malignancies, 101

symptoms, 96

treatment, 97–98

Rectal cancer, 54–56

Recurrence-free survival (RFS), 85

S

Screening

British Geriatric Society's recommendations, 33

conceptual screening framework, 31–32

early stage disease, 30–31

FOBT, 30

Screening (*cont.*)
geriatrician/general practitioner's
 role, 32–33
 issues, 31
 risks, 31
Selective internal radiation therapy
 (SIRT), 91
Short-course preoperative radiotherapy
 (SCPRT), 98, 99
Sitrains, 13
Socioeconomic status (SES), 6
Surgery
 age progression and trauma, 58–59
 colon cancer
 postoperative complications, 56–57
 postoperative mortality, 57–58
 comorbidity, 60–62
 older age and colorectal surgery, 59–60
 outcomes, 62
 rectal cancer
 complications, 54
 local recurrence, 56
 post-operative mortality, 54–55
 radio-chemotherapy, 56
 transanal endoscopic
 microsurgery, 56

T

Targeted therapy, mCRC
 bevacizumab
 efficacy outcomes, 147–148
 observational, expanded use studies,
 144–145
 polychemotherapy plus bevacizumab, 147
 RCT, 142–144
 related adverse events, 147, 149
 single-agent CT plus bevacizumab,
 145–147
 EGFR
 cetuximab(*see* Cetuximab)
 panitumumab, 154–155
 safety and efficacy data, 155–156
Telomeres, 13
Transanal endoscopic microsurgery (TEM), 56
Transarterial chemoembolization (TACE), 91

U

UK NHS Bowel Screening Programme, 30

V

Vulnerable Elders Survey-13 (VES-13), 103–104